The data were from a Phase I clinical study assessing IMGN901 used in combination with lenalidomide and dexamethasone to treat patients with CD56-expressing relapsed or relapsed/refractory multiple myeloma.
http://www.businesswire.com/news/home/20121210006407/en/ImmunoGen-Announces-IMGN901-Clinical-Data-Presented-ASH
http://www.businesswire.com/news/home/20121210006407/en/ImmunoGen-Announces-IMGN901-Clinical-Data-Presented-ASH
No comments:
Post a Comment